Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 18 of 18 for “"Schwannoma"”.
-
Analysis of Hippo pathway signalling in schwannoma and meningioma
… focuses on two tumours of the nervous system, schwannoma and meningioma. A large group of schwannomas and meningiomas display the inactivation of the NF2 gene. The NF2 gene codes for the tumour suppressor protein Merlin and its loss is associated with a multitude of pro-tumourigenic mechanisms …
-
Targeting Aldehyde Dehydrogenases in NF2-null Meningioma and Schwannoma
Meningioma and schwannoma are tumours of the brain and nervous system that are frequently driven by loss or mutation of the gene NF2, which encodes the tumour suppressor protein Merlin. Dysregulated Hippo pathway signalling, caused by NF2 loss, drives overexpression of aldehyde dehydrogenase 1A1 …
-
STUDY OF PHYSIO-PATHOLOGICAL MECHANISMS AT THE BASE OF SCHWANNOMA DEVELOPMENT
Schwannomas are the most common type of peripheral nerve tumor. Usually, schwannomas are benign, well‐circumscribed tumors clinging to peripheral nerves, consisting of a clonal population of Schwann cells (SCs), which often undergo cystic and degenerative changes. Most cases are sporadic, however, …
-
From bench to bedside : elucidating vestibular schwannoma pathobiology to devise effective pharmacotherapies
Vestibular schwannomas (VSs), the most common tumors of the cerebellopontine angle, arise from Schwann cells of the vestibular nerve. VSs can lead to sensorineural hearing loss (SNHL), disequilibrium, facial nerve paralysis, and brainstem compression. Treatment options available today are …
-
UNRAVELLING MECHANISMSOF SCHWANN CELLS IN VESTIBULAR SCHWANNOMA AND THEIR IMPACT ON HEARING LOSS.
Vestibular schwannoma (VS) is a benign peripheral nerve tumour arising from Schwann cells (SCs) of the vestibulocochlear nerve (VN) and represents the most common tumour of the cerebellopontine angle. Although the loss of NF2/merlin is a well-established driver of schwannoma (SCH) formation, likely …
-
The Role of Cellular Prion Protein in the Development of Schwannomas and other Merlin-Deficient Tumours
… with NF2 including; ependymomas, meningiomas and schwannomas. Merlin loss can also occur sporadically in all of these tumours and is associated with upregulation of various growth factor receptors and their relevant signalling pathways. At present the only treatment options for NF2 are surgery or …
-
The Role of Hippo Signalling in Merlin Null Tumours of the Nervous System
Meningiomas and schwannomas are mostly benign tumours of the nervous system that currently have no clinically approved treatments apart from surgical resection. The tumour suppressor Moesin-Ezrin-Radixin-Like Protein (Merlin) is deleted in 50-60% and 70% of meningiomas and schwannomas respectively. …
-
Investigating the role of TAM (TYRO3, AXL and MERTK) family receptors in merlin deficient tumours
… Type 2 (NF2)-related tumours including schwannomas, meningiomas and ependymomas. These tumours can also occur spontaneously in non-NF2 patients. The only available treatments for this group of tumours are surgery and radiosurgery/radiotherapy. Hence, there is an urgent need for new …
-
Exploring the Potential use of TEAD Inhibition as Part of a Combination Therapy for NF2-Deficient Schwannoma and Meningioma.
NF2-related Schwannomatosis is a genetic cancer predisposition syndrome, resulting in the development of schwannoma, meningioma and ependymoma tumours. Although surgical resection and adjuvant radiotherapy can be used, new avenues of therapeutic development are essential to target inoperable and …
-
Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours
Although schwannomas and meningiomas are generally benign and slow-growing, the mass effect of either tumour within the nervous system causes life-altering symptoms. Individuals with NF2-related schwannomatosis may develop schwannomas and meningiomas, increasing tumour burden. The primary treatment …
-
Endogenous retroviral proteins as potential drug targets for merlin-deficient tumours
… multiple tumours of the nervous system such as schwannomas, meningiomas and ependymomas. Current surgical treatments and radiotherapy for this group of tumours are not fully effective and there is an urgent need for new therapeutic options. Human endogenous retroviruses (HERVs) are retroviruses …
-
The Potential of CRL4-DCAF1 and KSR1 as Therapeutic Targets in Low-grade Merlin-Deficient Tumours
… is causative of tumour formation, including schwannoma, meningioma and ependymoma. These tumours can occur sporadically or as part of the genetic condition Neurofibromatosis type 2 (NF2) and cause significant morbidity. The current treatment options are restricted to surgery and radiotherapy, …
-
Identifying Common Therapeutic Targets in Merlin-deficient Brain Tumours
… multiple nervous system tumours, primarily schwannoma, meningioma and ependymoma. NF2 is characterised by loss of the tumour suppressor protein Merlin, caused by bi-allelic mutations of the encoding gene NF2 or by loss of heterozygosity. These tumours can occur either sporadically or as part …
-
The diversity of malignant rhabdoid tumours : a morphological, immunohistochemical and ultrastructural review of cases from the Red Cross Children's Hospital and Groote Schuur Hospitals
… neuro-ectodermal tumour, a malignant epithelioid Schwannoma and a possible undifferentiated hepatocellular carcinoma; all showing areas of extensive rhabdoid differentiation. Pseudo-rhabdoid cells in an additional two cases were also examined. These particular tumours were a nephroblastoma and a …
-
Deep Learning and Radiomics Based Outcome Prediction for Cancer Patients
… a deep learning model for joint vestibular schwannoma enlargement prediction and segmentation using initial diagnosis MR images to assist in patient management when a tumor is first discovered. The second part of the study aims to identify high-risk head and neck cancer (HNC) patients for …
-
Adaptation and learning in postural control
… implemented and studied. Patients scheduled for schwannoma surgery pre-treated with gentamicin, in order to produce a gradual sensory deafferentation, performed markedly better on the 6-month follow-up after surgery. Both compaired to before surgery and to other groups not treated with gentamicin …
-
Nerve tissue engineering using blends of Polyhydroxyalkanoates
… in single culture and in co-culture system with Schwannoma RN22 cells. NG108-15 cells displayed good growth and differentiation performance on all the PHA blend composites showing that both BGs (BG1 and BG2) have good biocompatibility at 2.5, 1.0 and 0.5 % w/v in the PHA blend solution. The …